See more : Roman DBDR Tech Acquisition Corp. (DBDR) Income Statement Analysis – Financial Results
Complete financial analysis of Tarsus Pharmaceuticals, Inc. (TARS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tarsus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ping An Securities Group (Holdings) Limited (0231.HK) Income Statement Analysis – Financial Results
- H3Enterprises, Inc. (HTRE) Income Statement Analysis – Financial Results
- London Security plc (LSC.L) Income Statement Analysis – Financial Results
- China Zhonghua Geotechnical Engineering Group Co., Ltd. (002542.SZ) Income Statement Analysis – Financial Results
- Nova Vision Acquisition Corporation (NOVVW) Income Statement Analysis – Financial Results
Tarsus Pharmaceuticals, Inc. (TARS)
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 17.45M | 25.82M | 57.03M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.59M | 955.00K | 2.08M | 246.00K | 74.00K | 1.00K |
| Gross Profit | 15.85M | 24.86M | 54.95M | -246.00K | -74.00K | -1.00K |
| Gross Profit Ratio | 90.87% | 96.30% | 96.36% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.31M | 42.62M | 41.71M | 18.83M | 3.16M | 901.00K |
| General & Administrative | 0.00 | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.70M | 44.95M | 25.40M | 8.17M | 1.14M | 449.00K |
| Other Expenses | 0.00 | 86.00K | -73.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 159.01M | 87.57M | 67.11M | 27.00M | 4.30M | 1.35M |
| Cost & Expenses | 160.61M | 88.53M | 69.18M | 27.00M | 4.30M | 1.35M |
| Interest Income | 10.34M | 3.50M | 36.00K | 188.00K | 40.00K | 0.00 |
| Interest Expense | 3.35M | 2.20M | 0.00 | 188.00K | 40.00K | 0.00 |
| Depreciation & Amortization | 877.00K | 789.00K | 606.00K | 246.00K | 74.00K | 1.00K |
| EBITDA | -131.67M | -59.11M | -13.17M | -26.56M | -4.56M | -1.35M |
| EBITDA Ratio | -754.69% | -229.03% | -18.55% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.16M | -62.71M | -12.16M | -27.00M | -4.30M | -1.35M |
| Operating Income Ratio | -820.53% | -242.92% | -21.32% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.27M | 617.00K | -1.62M | 188.00K | -371.00K | 32.00K |
| Income Before Tax | -135.89M | -62.10M | -13.77M | -26.81M | -4.67M | -1.32M |
| Income Before Tax Ratio | -778.89% | -240.53% | -24.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 55.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -135.89M | -62.09M | -13.83M | -26.81M | -4.67M | -1.32M |
| Net Income Ratio | -778.89% | -240.51% | -24.25% | 0.00% | 0.00% | 0.00% |
| EPS | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| EPS Diluted | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Weighted Avg Shares Out | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
| Weighted Avg Shares Out (Dil) | 29.38M | 24.62M | 20.55M | 20.32M | 19.51M | 4.29M |
Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?
Tarsus to Present at Upcoming Investor Conferences
Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential
Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Source: https://incomestatements.info
Category: Stock Reports